Brokerages Set Catalent, Inc. (NYSE:CTLT) PT at $56.83

Shares of Catalent, Inc. (NYSE:CTLT) have received a consensus recommendation of “Hold” from the ten research firms that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have given a hold rating and three have assigned a buy rating to the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $56.83.

CTLT has been the topic of several recent analyst reports. Barclays upped their target price on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research report on Friday, June 28th. StockNews.com initiated coverage on Catalent in a research note on Sunday. They issued a “sell” rating for the company. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a report on Thursday, July 11th.

Catalent Stock Performance

NYSE:CTLT opened at $59.80 on Friday. The firm’s fifty day simple moving average is $58.24 and its 200-day simple moving average is $56.91. The company has a quick ratio of 1.77, a current ratio of 2.51 and a debt-to-equity ratio of 1.37. The stock has a market cap of $10.82 billion, a PE ratio of -9.80, a price-to-earnings-growth ratio of 2.47 and a beta of 1.16. Catalent has a fifty-two week low of $31.80 and a fifty-two week high of $60.20.

Insider Activity

In related news, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction dated Friday, August 2nd. The stock was sold at an average price of $59.56, for a total transaction of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares in the company, valued at approximately $1,785,251.44. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. In other Catalent news, insider Ricky Hopson sold 662 shares of Catalent stock in a transaction that occurred on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now directly owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Alessandro Maselli sold 9,088 shares of the stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total value of $534,010.88. Following the transaction, the chief executive officer now directly owns 177,521 shares in the company, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Insiders have sold 14,810 shares of company stock worth $858,941 over the last three months. 0.31% of the stock is currently owned by corporate insiders.

Institutional Trading of Catalent

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CTLT. Truist Financial Corp boosted its position in shares of Catalent by 37.2% in the second quarter. Truist Financial Corp now owns 28,029 shares of the company’s stock worth $1,576,000 after acquiring an additional 7,600 shares during the last quarter. Millennium Management LLC boosted its holdings in shares of Catalent by 129.2% in the 2nd quarter. Millennium Management LLC now owns 4,079,964 shares of the company’s stock valued at $229,416,000 after purchasing an additional 2,299,784 shares during the last quarter. MBB Public Markets I LLC purchased a new stake in shares of Catalent during the 2nd quarter valued at $788,000. APG Asset Management N.V. increased its holdings in shares of Catalent by 26.8% during the 2nd quarter. APG Asset Management N.V. now owns 155,466 shares of the company’s stock worth $8,157,000 after buying an additional 32,900 shares during the last quarter. Finally, APG Asset Management US Inc. increased its holdings in shares of Catalent by 2.3% during the 2nd quarter. APG Asset Management US Inc. now owns 52,861 shares of the company’s stock worth $2,969,000 after buying an additional 1,172 shares during the last quarter.

About Catalent

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.